The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Open accessPublished version of a preprint
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic 1,2. Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms that determine such variable outcomes remain unresolved. Here we investigated CD4+ T cells that are reactive against the spike glycoprotein of SARS-CoV-2 in the peripheral blood of patients with COVID-19 and SARS-CoV-2-unexposed healthy donors. We detected spike-reactive CD4+ T cells not only in 83% of patients with COVID-19 but also in 35% of healthy donors. Spike-reactive CD4+ T cells in healthy donors were primarily active against C-terminal epitopes in the spike protein, which show a higher homology to spike glycoproteins of human endemic coronaviruses, compared with N-terminal epitopes. Spike-protein-reactive T cell lines generated from SARS-CoV-2-naive healthy donors responded similarly to the C-terminal region of the spike proteins of the human endemic coronaviruses 229E and OC43, as well as that of SARS-CoV-2. This results indicate that spike-protein cross-reactive T cells are present, which were probably generated during previous encounters with endemic coronaviruses. The effect of pre-existing SARS-CoV-2 cross-reactive T cells on clinical outcomes remains to be determined in larger cohorts. However, the presence of spike-protein cross-reactive T cells in a considerable fraction of the general population may affect the dynamics of the current pandemic, and has important implications for the design and analysis of upcoming trials investigating COVID-19 vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This cross-reactivity largely originates from previous exposure to circulating common cold coronaviruses [110-116].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [114]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SARS-CoV-2 infection elicits a Th1 CD4+ T cell response, with IFNγ and IL-2 being the primary cytokines produced by these cells and some TNFα production as well112,126-129.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
The cited source says what the claim attributes to it.
In the citing paper
“lymphocytes from 20% to 50% of unexposed donors display significant reactivity to SARS-CoV-2 Ag peptide pools (Figure 6).”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [114]
In the citing paper
“the T cell responses against SARS-CoV-2 are highly multi-antigenic and multi-specific, with tens of different epitopes recognized by CD4+ and CD8+ T cells in a given individual.”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [52]
In the citing paper
“The dominant cytokine produced by SARS-CoV-2-specific CD4+ T cells from COVID-19 patients is IFNγ (Braun et al., 2020; Grifoni et al., 2020; Rydyznski Moderbacher et al., 2020; Weiskopf et al., 2020), with a clear IFNγ, tumor necrosis factor (TNF), IL-2 protein signature of canonical Th1 cells (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Peng et al., 2020; Sekine et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“In contrast, the strikingly extended absence of SARS-CoV-2-specific CD4+ T cells was associated with severe or fatal COVID-19 (>day 22 PSO in some cases) (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Tan et al., 2020a).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“In contrast, substantial cross-reactive T cell memory has been reported, measurable in ∼28%–50% of people, depending on the study (Le Bert et al., 2020; Braun et al., 2020; Grifoni et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“Specifically, when compared to those with mild COVID-19, patients with severe disease generated a weaker T cell response to the N-terminal portion of the SARS-CoV-2 S protein, a region that includes the critical receptor-binding domain (RBD)128.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
In the citing paper
“Therefore, many individuals have existing memory T cells that were generated from endemic human coronavirus infections and can cross-react with SARS-CoV-2 epitopes, known as SARS-CoV-2 cross-reactive memory T cells128.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clustal W and Clustal X version 2.0
Larkin, M., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., López, R., et al. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm404 · Cited by 28,598
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Needleman, S. B., & Wunsch, C. D. (1970) · Journal of Molecular Biology · doi:10.1016/0022-2836(70)90057-4 · Cited by 11,288
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., Bleicker, T., Brünink, S., Schneider, J. A., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,266
Self-citationVirological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Self-citationWu, J. T., Leung, K., & Leung, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30260-9 · Cited by 4,389
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475
Cited by
Sorted by citations
Items 301–400 of 999
The Human Leukocyte Antigen Class II Immunopeptidome of the SARS-CoV-2 Spike Glycoprotein
Knierman, M. D., Lannan, M. B., Spindler, L. J., McMillian, C. L., Konrad, R. J., & Siegel, R. W. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108454 · Cited by 45
Long COVID a New Derivative in the Chaos of SARS-CoV-2 Infection: The Emergent Pandemic?
Fernández‐Lázaro, D., Sánchez-Serrano, N., Mielgo‐Ayuso, J., Garcı́a, J. L., Gonzalez-Bernal, J. J., & Seco‐Calvo, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245799 · Cited by 46
Harrington, P., de Lavallade, H., Doores, K. J., O’Reilly, A., Seow, J., Graham, C., Lechmere, T., Radia, D. H., Dillon, R. J., Shanmugharaj, Y., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01300-7 · Cited by 44
Deng, Y. L., Yu, L., Yang, R., & Tan, W. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00730-8 · Cited by 45
Reuken, P. A., Andreas, N., Grunert, P., Glöckner, S., Kamradt, T., & Stallmach, A. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab147 · Cited by 44
COVID-19: systemic pathology and its implications for therapy
Shen, Q., Li, J., Zhang, Z., Guo, S., Wang, Q., An, X., & Chang, H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.65911 · Cited by 51
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Ogbe, A., Pace, M. J., Bittaye, M., Tipoe, T., Adele, S., Alagaratnam, J., Aley, P. K., Ansari, M. A., Bara, A., Broadhead, S., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157031 · Cited by 44
Pahl, M. C., Coz, C. L., Su, C., Sharma, P. K., Thomas, R. M., Pippin, J. A., Cabrera, E. C., Johnson, M. E., Leonard, M. E., Lu, S., et al. (2022) · Genome biology · doi:10.1186/s13059-022-02691-1 · Cited by 44
Tissue-resident immunity in the lung: a first-line defense at the environmental interface
Zazara, D. E., Belios, I., Lücke, J., Zhang, T., & Giannou, A. D. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00964-2 · Cited by 48
Dhawan, M. K., Rabaan, A. A., Fawarah, M. M., Almuthree, S. A., Alsubki, R. A., Alfaraj, A. H., Mashraqi, M. M., Alshamrani, S., Abduljabbar, W. A., Alwashmi, A. S. S., et al. (2023) · Vaccines · doi:10.3390/vaccines11010101 · Cited by 45
Elfiky, A. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.577467 · Cited by 44
Meyers, L. M., Gutiérrez, A. H., Boyle, C., Terry, F. E., McGonnigal, B., Salazar, A. Μ., Princiotta, M. F., Martin, W. D., Groot, A. S. D., & Moise, L. (2021) · npj Vaccines · doi:10.1038/s41541-021-00331-6 · Cited by 44
Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients
Bibert, S., Guex, N., Lourenço, J., Brahier, T., Papadimitriou‐Olivgeris, M., Damonti, L., Manuel, O., Liechti, R., Götz, L., Tschopp, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666163 · Cited by 43
Lu, X., Hosono, Y., Nagae, M., Ishizuka, S., Ishikawa, E., Motooka, D., Ozaki, Y., Sax, N., Maeda, Y., Kato, Y., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20211327 · Cited by 44
McNaughton, A. L., Paton, R. S., Edmans, M. D., Youngs, J., Wellens, J., Phalora, P. K., Fyfe, A. J., Belij‐Rammerstorfer, S., Bolton, J. S., Ball, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.156372 · Cited by 46
Saggau, C., Martini, G. R., Rosati, E., Meise, S., Messner, B., Kamps, A.-K., Bekel, N., Gigla, J. B., Rose, R., Voß, M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.003 · Cited by 42
HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients
Steiner, S., Sotzny, F., Bauer, S., Na, I., Schmueck‐Henneresse, M., Corman, V. M., Schwarz, T., Drosten, C., Wendering, D. J., Behrends, U., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.607918 · Cited by 43
Self-citationPreexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Bilich, T., Roerden, M., Maringer, Y., Nelde, A., Heitmann, J. S., Dubbelaar, M. L., Peter, A., Hörber, S., Bauer, J., Rieth, J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0191 · Cited by 41
Severe respiratory viral infections: T-cell functions diverging from immunity to inflammation
Yunis, J., Short, K. R., & Yu, D. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2022.12.008 · Cited by 40
Human Coronavirus OC43 as a Low-Risk Model to Study COVID-19
Kim, M. I., & Lee, C.-H. (2023) · Viruses · doi:10.3390/v15020578 · Cited by 47
Olbrich, L., Castelletti, N., Schälte, Y., Garí, M., Pütz, P., Bakuli, A., Pritsch, M., Kroidl, I., Saathoff, E., Noller, J. M. G., et al. (2021) · Journal of General Virology · doi:10.1099/jgv.0.001653 · Cited by 39
Wu, D., Kolesnikov, A. V., Yin, R. M., Guest, J. D., Gowthaman, R., Shmelev, A., Serdyuk, Y. V., Dianov, D. V., Efimov, G. A., Pierce, B. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27669-8 · Cited by 45
SARS-CoV-2—The Role of Natural Immunity: A Narrative Review
Diani, S., Leonardi, E. A., Cavezzi, A., Ferrari, S., Iacono, O., Limoli, A., Bouslenko, Z., Natalini, D., Conti, S., Mantovani, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216272 · Cited by 44
Santer, D. M., Li, D., Ghosheh, Y., Zahoor, M. A., Prajapati, D., Hansen, B. E., Tyrrell, D. L., Feld, J. J., & Gehring, A. J. (2022) · Nature Communications · doi:10.1038/s41467-022-34709-4 · Cited by 44
Dalakas, M. C., Bitzogli, K., & Alexopoulos, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627285 · Cited by 42
Verhagen, J., van der Meijden, E. D., Lang, V., Kremer, A. E., Völkl, S., Mackensen, A., Aigner, M., & Kremer, A. N. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13627 · Cited by 40
Westheim, A. J. F., Bitorina, A. V., Theys, J., & Shiri‐Sverdlov, R. (2021) · Obesity Reviews · doi:10.1111/obr.13313 · Cited by 44
Molecular immunological aspects of diagnostics, prevention and treatment of coronavirus infection
Гудима, Г. О., Khaitov, R. M., Kudlay, D. A., & Khaitov, M. R. (2021) · Immunologiya · doi:10.33029/0206-4952-2021-42-3-198-210 · Cited by 46
Schrörs, B., Riesgo-Ferreiro, P., Sorn, P., Gudimella, R., Bukur, T., Rösler, T., Löwer, M., & Şahin, U. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249254 · Cited by 41
Durability of SARS-CoV-2–Specific T-Cell Responses at 12 Months Postinfection
Lu, Z., Laing, E. D., DaMata, J. P., Pohida, K., Tso, M. S., Samuels, E. C., Epsi, N. J., Dorjbal, B., Lake, C. M., Richard, S. A., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab543 · Cited by 44
An ACP-Based Parallel Approach for Color Image Encryption Using Redundant Blocks
Zheng, W., Yan, L., Gou, C., & Wang, F. (2021) · IEEE Transactions on Cybernetics · doi:10.1109/tcyb.2021.3105568 · Cited by 43
Sharun, K., Tiwari, R., Yatoo, M. I., Natesan, S., Megawati, D., Singh, K. P., Michalak, I., & Dhama, K. (2022) · Narra J · doi:10.52225/narra.v2i3.92 · Cited by 42
Deciphering SARS-CoV-2 Virologic and Immunologic Features
Lebeau, G., Vagner, D., Frumence, É., Ah-Pine, F., Guillot, X., Nobécourt, E., Raffray, L., & Gasque, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165932 · Cited by 54
Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity
Loos, C., Atyeo, C. G., Fischinger, S., Burke, J. S., Slein, M. D., Streeck, H., Lauffenburger, D. A., Ryan, E. T., Charles, R. C., & Alter, G. (2020) · mSphere · doi:10.1128/msphere.00622-20 · Cited by 39
Brüssow, H. (2020) · Environmental Microbiology · doi:10.1111/1462-2920.15302 · Cited by 54
The past, current and future epidemiological dynamic of SARS-CoV-2
Balloux, F., Tan, C. C. S., Swadling, L., Richard, D., Jenner, C., Maini, M. K., & van Dorp, L. (2022) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac003 · Cited by 41
Kumar, V. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106980 · Cited by 42
Anft, M., Paniskaki, K., Blazquez‐Navarro, A., Doevelaar, A., Seibert, F. S., Hölzer, B., Skrzypczyk, S., Kohut, E., Kurek, J., Zapka, J., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.001 · Cited by 41
Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies?
Jonigk, D. D., Werlein, C., Acker, T., Aepfelbacher, M., Amann, K., Baretton, G. B., Barth, P., Bohle, R. M., Büttner, A., Büttner, R., et al. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03319-2 · Cited by 44
Cohen, L., Spiro, D. J., & Viboud, C. G. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010591 · Cited by 42
Single-Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 + T CellsPreprint
Meckiff, B. J., Ramírez-Suástegui, C., Fajardo, V., Chee, S., Kusnadi, A., Simon, H. A., Grifoni, A., Pelosi, E., Weiskopf, D., Sette, A., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3641939 · Cited by 47
Eser, T. M., Baranov, O., Huth, M., Ahmed, M. I. M., Deák, F., Held, K., Lin, L., Pekayvaz, K., Leunig, A., Nicolai, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38020-8 · Cited by 41
Chen, X., Huang, J., Huang, Y., Chen, J., Huang, Y., Jiang, X., & Shi, Y. (2020) · Human Immunology · doi:10.1016/j.humimm.2020.08.006 · Cited by 39
Immune memory in convalescent patients with asymptomatic or mild COVID-19
Long, Q., Jia, Y., Wang, X., Deng, H., Cao, X., Yuan, J., Fang, L., Cheng, X.-R., Luo, C., He, A.-R., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00250-9 · Cited by 41
Pothast, C. R., Dijkland, R. C., Thaler, M., Hagedoorn, R. S., Kester, M. G. D., Wouters, A. K., Hiemstra, P. S., van Hemert, M. J., Gras, S., Falkenburg, J. H. F., et al. (2022) · eLife · doi:10.7554/elife.82050 · Cited by 40
What could explain the late emergence of COVID-19 in Africa?
Lalaoui, R., Bakour, S., Raoult, D., Verger, P., Sokhna, C., Devaux, C. A., Pradines, B., & Rolain, J. (2020) · New Microbes and New Infections · doi:10.1016/j.nmni.2020.100760 · Cited by 38
How could we forget immunometabolism in SARS-CoV2 infection or COVID-19?
Kumar, V. (2020) · International Reviews of Immunology · doi:10.1080/08830185.2020.1840567 · Cited by 39
Pichler, D., Baumgartner, M. R., Kimpel, J., Rössler, A., Riepler, L., Bates, K., Fleischer, V., von Laer, D., Borena, W., & Würzner, R. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab300 · Cited by 39
Gomes, S. M. R., Brito, A. C. D. S., PEREIRA-MANFRO, W. F., Alves, M. R., Ribeiro, R. S. D. A., da Cal, M. S., Lisboa, V. D. C., de Abreu, D. P. B., Castilho, L. R., Pôrto, L. C., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283983 · Cited by 41
Pieren, D. K. J., Kuguel, S. G., Rosado, J., Robles, A. G., Rey-Cano, J., Mancebo-Pérez, C., Esperalba, J., Falcó, V., Buzón, M. J., & Genescà, M. (2023) · Nature Communications · doi:10.1038/s41467-023-37559-w · Cited by 38
Lee, P., Kim, C.-U., Seo, S. H., & Kim, D. (2021) · Immune Network · doi:10.4110/in.2021.21.e4 · Cited by 40
Jin, X., Ding, Y., Sun, S., Wang, X., Zhou, Z., Liu, X. K., Li, M., Chen, X., Shen, A., Wu, Y., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00784-8 · Cited by 39
Winkley, K., Banerjee, D., Louiselle, D. A., Biswell, R. L., Posey, N., Fatheree, K., McDanel, S., Bradley, T., Moffatt, M. E., Koseva, B. S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95532-3 · Cited by 37
Gupta, R., & Misra, A. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108267 · Cited by 38
Fischer, D. S., Ansari, M., Wagner, K. I., Jarosch, S., Huang, Y., Mayr, C. H., Strunz, M., Lang, N. J., D’Ippolito, E., Hammel, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24730-4 · Cited by 41
Huzly, D., Panning, M., Smely, F., Enders, M., Komp, J., Falcone, V., & Steinmann, D. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105098 · Cited by 38
Targets and cross-reactivity of human T cell recognition of common cold coronaviruses
Tarke, A., Zhang, Y., Methot, N., Narowski, T. M., Phillips, E. J., Mallal, S. A., Frazier, A., Filaci, G., Weiskopf, D., Dan, J. M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101088 · Cited by 39
Severe SARS-CoV-2 disease in the context of a NF-κB2 loss-of-function pathogenic variant
Abraham, R. S., Marshall, J. M., Kuehn, H. S., Rueda, C. M., Gibbs, A., Guider, W., Stewart, C. A., Rosenzweig, S. D., Wang, H., Jean, S., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.09.020 · Cited by 38
Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients
Phadke, V. K., Scanlon, N., Jordan, S. C., & Rouphael, N. (2021) · Current Transplantation Reports · doi:10.1007/s40472-021-00322-5 · Cited by 38
Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era
Coyle, P. K., Gocke, A. R., Vignos, M., & Newsome, S. D. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01761-3 · Cited by 39
Is the oral microbiome a source to enhance mucosal immunity against infectious diseases?
Zenobia, C., Herpoldt, K., & Freire, M. (2021) · npj Vaccines · doi:10.1038/s41541-021-00341-4 · Cited by 40
Alefishat, E. A., Jelinek, H. F., Mousa, M., Tay, G. K., & AlSafar, H. S. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.01.007 · Cited by 39
Zhao, W., Chen, W., Li, J., Chen, M., Li, Q., Lv, M., Zhou, S., Bai, S., Wang, Y., Zhang, L., et al. (2022) · mBio · doi:10.1128/mbio.00181-22 · Cited by 37
Lin, J., Law, R., Korosec, C. S., Zhou, C. Y., Koh, W. H., Ghaemi, M. S., Samaan, P., Ooi, H. K., Matveev, V., Yue, F., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00509-22 · Cited by 38
Fiore, J. R., Centra, M., Carlo, A. D., Granato, T., Rosa, A., Sarno, M., Feo, L. D., Stefano, M. D., Errico, M. D., Caputo, S. L., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26425 · Cited by 36
Pernio (Chilblains), SARS-CoV-2, and COVID Toes Unified Through Cutaneous and Systemic Mechanisms
Cappel, M. A., Cappel, J. A., & Wetter, D. A. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.01.009 · Cited by 36
Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review
Shafqat, A., Shafqat, S., Alsalameh, S., Kashir, J., AlKattan, K. M., & Yaqinuddin, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835104 · Cited by 37
van der Ploeg, K., Kirosingh, A. S., Mori, D. A., Chakraborty, S., Hu, Z., Sievers, B. L., Jacobson, K. B., Bonilla, H. F., Parsonnet, J., Andrews, J. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100640 · Cited by 36
de Castro, J. T., de Azevedo, P. O., Fumagalli, M. J., Hojo-Souza, N. S., Salazar, N., Almeida, G. G., Oliveira, L. I., Faustino, L., Antonelli, L. R. D. V., Marçal, T. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32547-y · Cited by 37
Durairajan, S. S. K., Singh, A. K., Saravanan, U. B., Namachivayam, M., Radhakrishnan, M., Huang, J., Dhodapkar, R., & Zhang, H. (2023) · Viruses · doi:10.3390/v15061231 · Cited by 37
Cooper, R. S., Fraser, A. R., Smith, L. M., Burgoyne, P., Imlach, S. N., JARVIS, L. M., Turner, D. M., Zahra, S., Turner, M. L., & Campbell, J. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598402 · Cited by 33
Hamelin, D. J., Fournelle, D., Grenier, J., Schockaert, J., Kovalchik, K. A., Kubiniok, P., Mostefai, F., Duquette, J. D., Saab, F., Sirois, I., et al. (2021) · Cell Systems · doi:10.1016/j.cels.2021.09.013 · Cited by 35
Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
Su, S., Li, W., & Jiang, S. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.01.009 · Cited by 32
Molodtsov, I. A., Kegeles, E., Mitin, A. N., Mityaeva, O. N., Musatova, O. E., Panova, A. E., Pashenkov, M. V., Peshkova, I. O., Alsalloum, A., Asaad, W., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac278 · Cited by 33
Becerra‐Artiles, A., Calvo‐Calle, J. M., Co, M. D. T., Nanaware, P. P., Cruz, J., Weaver, G. C., Lu, L., Forconi, C. S., Finberg, R. W., Moormann, A. M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110952 · Cited by 36
Khoo, W. H., Jackson, K., Phetsouphanh, C., Zaunders, J., Alquicira-Hernández, J., Yazar, S., Ruiz‐Diaz, S., Singh, M., Dhenni, R., Kyaw, W., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109209 · Cited by 31
Steffen, T. L., Stone, E. T., Hassert, M., Geerling, E., Grimberg, B. T., Espino, A. M., Pantoja, P., Climent, C., Hoft, D. F., George, S. L., et al. (2020) · doi:10.1101/2020.08.21.261727 · Cited by 25
Behrens, G. M. N., Cossmann, A., Stankov, M. V., Schulte, B., Streeck, H., Förster, R., Bošnjak, B., Willenzon, S., Boeck, A.-L., Tran, A. T., et al. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00334-1 · Cited by 34
Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary Hospital in Madrid
Calles, A., Aparicio, I., Alva, M., Beranek, M. B., Gutiérrez, N., Soto, J. A., Arregui, M., Tirado, V. C., Álvarez, E. L., del Monte-Millán, M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01777 · Cited by 35
Immunotherapies and immunomodulatory approaches in clinical trials - a mini review
Yatoo, M. I., Hamid, Z., RATHER, I. A., Nazir, Q. U. A., Bhat, R. A., Haq, A. U., Magray, S. N., Haq, Z. U., Sah, R., Tiwari, R., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1871295 · Cited by 36
Generation of Glucocorticoid Resistant SARS-CoV-2 T-Cells for Adoptive Cell Therapy
Başar, R., Uprety, N., Ensley, E. L., Daher, M., Klein, K. L., Martínez, F. D., Aung, F. M., Shanley, M., Hu, B., Gokdemir, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.109432 · Cited by 33
Rausch, L., Lutz, K., Schifferer, M., Winheim, E., Gruber, R., Oesterhaus, E. F., Rinke, L., Hellmuth, J. C., Scherer, C., Muenchhoff, M., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12173 · Cited by 31
Nesterenko, P. A., McLaughlin, J., Tsai, B. L., Sojo, G. B., Cheng, D., Zhao, D. Y., Mao, Z., Bangayan, N. J., Obusan, M. B., Su, Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110167 · Cited by 33
Two sides of the same coin: Protective versus pathogenic CD4 + resident memory T cells
Oja, A. E., van Lier, R. A. W., & Hombrink, P. (2022) · Science Immunology · doi:10.1126/sciimmunol.abf9393 · Cited by 35
Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4+ T cell recognition
Tye, E. X. C., Jinks, E., Haigh, T. A., Kaul, B., Patel, P., Parry, H., Newby, M. L., Crispin, M., Kaur, N., Moss, P. A. H., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01351-7 · Cited by 37
Primard, C., Monchâtre-Leroy, É., del Campo, J. M., Valsesia, S., Nikly, E., Chevandier, M., Boué, F., Servat, A., Wasniewski, M., Meyer, E. P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188605 · Cited by 34
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
Heitmann, J. S., Tandler, C., Marconato, M., Nelde, A., Habibzada, T., Rittig, S. M., Tegeler, C. M., Maringer, Y., Jaeger, S. U., Denk, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40758-0 · Cited by 37
Ortega, M. R., Spisak, N., Mora, T., & Walczak, A. M. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010652 · Cited by 34
Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection
Escudero-Pérez, B., Lawrence, P., & Castillo‐Olivares, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1156758 · Cited by 37
Demers‐Mathieu, V., DaPra, C., Mathijssen, G. B., Sela, D. A., Järvinen, K. M., Seppo, A., Fels, S., & Medo, E. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041749 · Cited by 32
Balz, K., Kaushik, A., Chen, M., Cemič, F., Heger, V., Renz, H. E., Nadeau, K. C., & Skevaki, C. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-84320-8 · Cited by 33
Shi, Y. P., Feng, X., Lin, L., Wang, J., Chi, J., Wu, B., Zhou, G., Yu, F., Xu, Q., Liu, D., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.02.038 · Cited by 33
Spoerl, S., Kremer, A. N., Aigner, M., Eisenhauer, N., Koch, P., Meretuk, L., Löffler, P., Tenbusch, M., Maier, C., Überla, K., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202049135 · Cited by 34
Brand, I., Gilberg, L., Bruger, J., Garí, M., Wieser, A., Eser, T. M., Frese, J., Ahmed, M. I. M., Rubio‐Acero, R., Noller, J. M. G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.688436 · Cited by 34
Gouma, S., Weirick, M. E., Bolton, M. J., Arevalo, C. P., Goodwin, E. C., Anderson, E. M., McAllister, C. M., Christensen, S. R., Dunbar, D., Fiore, D., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150449 · Cited by 30
The Immune Response to SARS-CoV-2 and Variants of Concern
Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 36
Fernández‐González, M., Agulló, V., Padilla, S., García, J. A., García‐Abellán, J., Botella, Á., Mascarell, P., Ruiz‐García, M., Masiá, M., & Gutiérrez, F. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1021 · Cited by 34
Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months
Kaaijk, P., Pimentel, V. O., Emmelot, M. E., Poelen, M. C. M., Çevirgel, A., Schepp, R. M., den Hartog, G., Reukers, D. F. M., Beckers, L., van Beek, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.817876 · Cited by 32
Johansson, A. M., Malhotra, U., Kim, Y. G., Gomez, R., Krist, M. P., Wald, A., Koelle, D. M., & Kwok, W. W. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010203 · Cited by 35
CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients
Weber, S., Kehl, V., Erber, J., Wagner, K. I., Jetzlsperger, A.-M., Burrell, T., Schober, K., Schommers, P., Augustin, M., Crowell, C. S., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268530 · Cited by 36
Metadata
- Authors
- Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., Baysal, E., Mangold, M., Henze, L., Lauster, R., Mall, M. A., Beyer, K., Röhmel, J., Voigt, S., Schmitz, J., Miltenyi, S., Demuth, I., Müller, M. A., Hocke, A., Witzenrath, M., Suttorp, N., Kern, F., Reimer, U., Wenschuh, H., Drosten, C., Corman, V. M., Giesecke-Thiel, C., Sander, L. E., & Thiel, A.
- Affiliations
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité – Universitätsmedizin Berlin (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Technische Universität Berlin (DE)
- Robert Koch Institute (DE)
- Miltenyi Biotec (Germany) (DE)
- Brighton and Sussex Medical School (GB)
- JPT Peptide Technologies (Germany) (DE)
- Corresponding author
- Sander, Leif Erik
- Thiel, Andreas
- ORCID
- Braun, Julian
- Loyal, Lucie
- Frentsch, Marco
- Wendisch, Daniel
- Georg, Philipp
- Kurth, Florian
- Hippenstiel, Stefan
- Dingeldey, Manuela
- Fauchere, Florent
- Baysal, Emre
- Mangold, Maike
- Henze, Larissa
- Mall, Marcus A.
- Beyer, Kirsten
- Voigt, Sebastian
- Demuth, Ilja
- Müller, Marcel A.
- Hocke, Andreas
- Witzenrath, Martin
- Suttorp, Norbert
- Kern, Florian
- Reimer, Ulf
- Drosten, Christian
- Corman, Victor M.
- Giesecke-Thiel, Claudia
- Sander, Leif Erik
- Thiel, Andreas
- Venue
- Nature
- Published
- 2020-07-29
- Volume
- 587
- Issue
- 7833
- Pages
- 270-274
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3045971896
- Cited by
- 1,310
- References
- 41
- Citations by year
- 2026: 16 · 2025: 37 · 2024: 91 · 2023: 143 · 2022: 283 · 2021: 480 · 2020: 259
- FWCI
- 38.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Sussex Research Online (University of Sussex) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft (KFO 339, SFB‐TR84)
- Bundesministerium für Bildung und Forschung
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, CD4+ T cells, spike protein, cross-reactive T cells, HCoV-229E, HCoV-OC43, C-terminal epitope, T cell immunity, COVID-19 vaccine design, healthy donors
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Aged, Aged, 80 and over, Cell Line, Cross Reactions, Female, Humans, Lymphocyte Activation, Male, Middle Aged, Pneumonia, Viral, CD4-Positive T-Lymphocytes, Coronavirus Infections, Epitopes, T-Lymphocyte, Coronavirus 229E, Human, Coronavirus OC43, Human, Pandemics, Coronavirus NL63, Human, Healthy Volunteers, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
